Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Fresenius Kabi AG

www.fresenius-kabi.com

Latest From Fresenius Kabi AG

Off-Patent Personnel Moves In 2023 Reflect Growing Interest In Innovator Space

Executive changes at both Viatris and Teva in 2023 saw the companies shift their focus towards the innovator industry. Plus, trade groups saw some significant personnel shakeups, Alvotech expressed hope that new hires would help to resolve manufacturing approval issues, Biocon made changes to its management structure, and more.

Executive Changes Leadership

Big Pharma Shouts, Generics And Biosimilars Whisper: M&A In 2023

“A lot of companies are hurting because of the higher interest rates,” one major CEO observed recently, summing up a year which saw little headline-grabbing news on the M&A front for generic and biosimilar sponsors.

M & A Deals

New’s We’re Watching: Apple/Masimo Patent Fight Update; Acutus Winds Down; Illumina Bails On Grail

Medtech Insight's News We're Watching highlights medtech industry developments that you may have missed over the last few weeks. In addition to the big news from Acutus, Apple, and Illumina, Masimo scored an important FDA clearance, Beta Bionics announced the US launch of its iLet bionic pancreas for Dexcom’s G7 CGM, and more.

News We're Watching Commercial

Bio-Thera Delivers Positive Phase III Results For Stelara Biosimilar

Bio-Thera has announced positive Phase III results for its ustekinumab biosimilar candidate BAT2206, demonstrating that the product is highly similar to originator Stelara in patients with moderate to severe plaque psoriasis. 

Biosimilars Clinical Trials
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
  • Medical Devices
    • Infusion Therapy Equipment and Supplies
  • Other Names / Subsidiaries
    • mAbxience S.L.
UsernamePublicRestriction

Register